Last €9.45 EUR
Change Today -0.09 / -0.94%
Volume 98.8K
THR On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
Berlin
As of 11:36 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for thrombogenics nv (THR)

Year over year, ThromboGenics NV has seen their bottom line shrink from €30.4M EUR to €26.4M EUR despite an increase in revenues from €75.1M EUR to €112.8M EUR. An increase in the percentage of sales devoted to SGA costs from 35.67% to 43.63% was a key component in the falling bottom line in the face of rising revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of Euros
As of:Dec 31
2010
EUR
Dec 31
2011
EUR
Dec 31
2012
Reclassified
EUR
Dec 31
2013
EUR
4 Year
Trend
Revenues6.12.475.1112.8
Other Revenues0.00.0----
TOTAL REVENUES6.22.575.1112.8
Cost of Goods Sold0.50.23.16.4
GROSS PROFIT5.62.372.0106.4
Selling General & Admin Expenses, Total5.511.426.849.2
R&D Expenses18.719.716.131.7
Other Operating Expenses-3.8-4.10.00.0
OTHER OPERATING EXPENSES, TOTAL20.327.042.980.9
OPERATING INCOME-14.7-24.829.125.5
Interest Expense0.00.00.00.0
Interest and Investment Income0.71.42.01.4
NET INTEREST EXPENSE0.71.42.01.4
Currency Exchange Gains (Loss)0.01.7-0.7-0.5
Other Non-Operating Income (Expenses)0.00.00.00.0
EBT, EXCLUDING UNUSUAL ITEMS-13.9-21.630.526.4
Gain (Loss) on Sale of Investments0.00.00.00.0
EBT, INCLUDING UNUSUAL ITEMS-13.9-21.630.426.4
Income Tax Expense0.00.00.00.0
Earnings from Continuing Operations-13.9-21.630.426.4
NET INCOME-13.9-21.630.426.4
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-13.9-21.630.426.4
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-13.9-21.630.426.4
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THR:BB €9.45 EUR -0.09

THR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THR.
View Industry Companies
 

Industry Analysis

THR

Industry Average

Valuation THR Industry Range
Price/Earnings 13.0x
Price/Sales 3.0x
Price/Book 1.3x
Price/Cash Flow 12.7x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.